Björn Lisboa, MD, PhD

Articles by Björn Lisboa, MD, PhD

Paclitaxel and Epirubicin as First-Line Therapy for Patients With Metastatic Breast Cancer

ByHans-Joachim Lück, MD,Andreas Du Bois, MD, PhD,Christoph Thomssen, MD, PhD,Björn Lisboa, MD, PhD,Michael Untch, MD, PhD,Günther Köhler, MD, PhD,Detlev Hecker, PhD,Klaus Diergarten, MD

April 1st 1997

Paclitaxel (Taxol) has aroused considerable interest for its high single-agent activity in breast cancer and novel mechanism of action. Epirubicin (Farmorubicin), the 4'epimer of doxorubicin (Adriamycin), also has high activity in

Latest Updated Articles

Paclitaxel and Epirubicin as First-Line Therapy for Patients With Metastatic Breast Cancer
Published: April 1st 1997 | Updated:

Björn Lisboa, MD, PhD

Articles by Björn Lisboa, MD, PhD

Paclitaxel and Epirubicin as First-Line Therapy for Patients With Metastatic Breast Cancer

Latest Updated Articles

Trending on CancerNetwork

ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice

Frontline Tislelizumab Combo Improves Long-Term Survival in ES-SCLC

ctDNA Status May Determine Adjuvant Immunotherapy Benefit in MIBC

FDA Approves Revumenib in R/R NPM1-Mutant AML

Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment